Labeled circular DNA molecules for analysis of DNA topology, and topoisomerases and for drug screening

Patent metadata

Field	Value
Publication number	US-10150987-B2
Application number	US-201715857056-A
Country	US
Kind code	B2
Filing date	Dec 28, 2017
Priority date	Oct 5, 2015
Publication date	Dec 11, 2018
Grant date	Dec 11, 2018

Abstract

The present invention provides labeled circular plasmid DNA molecules for studying DNA topology and topoisomerases. The molecules of the present invention also provide tools for high throughput drug screening for inhibitors of DNA gyrases and DNA topoisomerases for anticancer drug discovery and antibiotics discovery.

First claim

The invention claimed is:

1. A method of screening for inhibitors targeting DNA topoisomerases, DNA gyrases, DNA endonucleases, or DNA nicking endonucleases, the method comprising:
providing a sample suspected of containing an inhibitor of a DNA topoisomerase, DNA gyrase, DNA endonuclease, or DNA nicking endonuclease;
adding a circular supercoiled double-stranded plasmid comprising a nucleic acid sequence comprising an adenosine-thymidine dinucleotide repeat (AT) n sequence, characterized in that n is at least 12, the (AT) n sequence comprises at least one fluorophore and at least one quencher, each conjugated to a deoxythymidine (dT), and the fluorophore-conjugated dT and the quencher-conjugated dT are separated by at least 14 nucleotides and are located on the same DNA strand to the sample suspected of containing an inhibitor of a DNA topoisomerase, DNA endonuclease, or DNA nicking endonuclease; or
adding a circular relaxed double-stranded plasmid comprising a nucleic acid sequence comprising an adenosine-thymidine dinucleotide repeat (AT) n sequence, characterized in that n is at least 12, the (AT) n sequence comprises at least one fluorophore and at least one quencher, each conjugated to a deoxythymidine (dT), and the fluorophore-conjugated dT and the quencher-conjugated dT are separated by at least 14 nucleotides and are located on the same DNA strand to the sample suspected of containing an inhibitor of a DNA gyrase,
adding a DNA topoisomerase, DNA endonuclease, or DNA nicking endonuclease to the sample containing the circular supercoiled double-stranded plasmid; or
adding a DNA gyrase to the sample containing the circular relaxed double-stranded plasmid;
quantifying fluorescence in the sample; and
quantifying the amount of inhibitor present in the sample based on the fluorescence measured in the sample compared to the fluorescence measured in a control sample containing only the DNA topoisomerase, DNA endonuclease, or DNA nicking endonuclease and the circular supercoiled double-stranded plasmid or containing only the DNA gyrase and the circular relaxed double-stranded plasmid;
characterized in that the fluorescence in the control sample containing the DNA topoisomerase, DNA endonuclease, or DNA nicking endonuclease is high due to the interconversion of the circular supercoiled double-stranded plasmid to a relaxed conformation in the presence of the DNA topoisomerase, DNA endonuclease, or DNA nicking endonuclease; and
the fluorescence in the sample is lower than in the control sample if the sample contains an inhibitor of the DNA topoisomerase, DNA endonuclease, or DNA nicking endonuclease; or
characterized in that the fluorescence in the control sample containing the DNA gyrase is low due to the interconversion of the circular relaxed double-stranded plasmid to a supercoiled conformation in the presence of the DNA gyrase; and
the fluorescence in the sample is higher than in the control sample if the sample contains an inhibitor of the DNA gyrase.

2. The method, according to claim 1 , comprising:
adding a circular supercoiled double-stranded plasmid or a circular relaxed double-stranded plasmid both comprising a nucleic acid sequence comprising an (AT) n sequence, characterized in that n is at least 12, the (AT) n sequence comprises at least one fluorophore and at least one quencher, each conjugated to a deoxythymidine (dT), and the fluorophore-conjugated dT and the quencher-conjugated dT are separated by at least 14 nucleotides and are located on the opposite DNA strand.

3. The method according to claim 1 , comprising:
adding a circular supercoiled double-stranded plasmid or a circular relaxed double-stranded plasmid both comprising a nucleic acid sequence comprising an (AT) n sequence, characterized in that n is at least 12, the (AT) n sequence comprises at least one fluorophore and at least one quencher, each conjugated to a deoxythymidine (dT), and the fluorophore-conjugated dT and the quencher-conjugated dT are separated by 25 nucleotides and are located on the same DNA strand.

4. The method, according to claim 1 , comprising:
adding a circular supercoiled double-stranded plasmid or a circular relaxed double-stranded plasmid both comprising a nucleic acid sequence comprising an (AT) n sequence, characterized in that n is at least 12, the (AT) n sequence comprises at least one fluorophore and at least one quencher, each conjugated to a deoxythymidine (dT), and the fluorophore-conjugated dT and the quencher-conjugated dT are separated by 25 nucleotides and are located on the opposite DNA strand.

5. The method according to claim 1 , characterized in that a half-maximal increase in fluorescence in the control sample containing only a DNA topoisomerase occurs within 30 seconds.

6. The method according to claim 1 , characterized in that a half-maximal increase in fluorescence in the control sample containing only a DNA nicking endonuclease occurs within 20 seconds.

7. A method of screening for inhibitors targeting RNAses, the method comprising:
providing a sample suspected of containing an inhibitor of a RNAse;
adding a circular supercoiled double-stranded plasmid comprising a nucleic acid sequence comprising an adenosine-thymidine dinucleotide repeat (AT) n sequence, characterized in that n is at least 12, the (AT) n sequence comprises at least one fluorophore and at least one quencher, each conjugated to a deoxythymidine (dT), and the fluorophore-conjugated dT and the quencher-conjugated dT are separated by at least 14 nucleotides and are located on the same DNA strand, and further comprising a nucleic acid sequence comprising at least one RNA oligomer located on the same strand as the at least one fluorophore and the at least one quencher;
adding a RNAse;
quantifying fluorescence in the sample; and
quantifying the amount of inhibitor present in the sample based on the fluorescence measured in the sample compared to the fluorescence measured in a control sample containing only the RNAse and the circular supercoiled double-stranded plasmid;
characterized in that the fluorescence in the control sample is high due to the interconversion of the circular supercoiled double-stranded plasmid to a relaxed conformation in the presence of the RNAse; and
the fluorescence in the sample is lower than in the control sample if the sample contains an inhibitor of the RNAse.

8. The method, according to claim 7 , comprising:
adding a circular supercoiled double-stranded plasmid comprising a nucleic acid sequence comprising an (AT) n sequence, characterized in that n is at least 12, the (AT) n sequence comprises at least one fluorophore and at least one quencher, each conjugated to a deoxythymidine (dT), and the fluorophore-conjugated dT and the quencher-conjugated dT are separated by at least 14 nucleotides and are located on the opposite DNA strand.

9. The method according to claim 7 , comprising:
adding a circular supercoiled double-stranded plasmid comprising a nucleic acid sequence comprising an (AT) n sequence, characterized in that n is at least 12, the (AT) n sequence comprises at least one fluorophore and at least one quencher, each conjugated to a deoxythymidine (dT), and the fluorophore-conjugated dT and the quencher-conjugated dT are separated by 25 nucleotides and are located on the same DNA strand.

10. The method, according to claim 7 , comprising:
adding a circular supercoiled double-stranded plasmid comprising a nucleic acid sequence comprising an (AT) n sequence, characterized in that n is at least 12, the (AT) n sequence comprises at least one fluorophore and at least one quencher, each conjugated to a deoxythymidine (dT), and the fluorophore-conjugated dT and the quencher-

Assignees

• Leng Fenfei
• The Florida International Univ Board Of Trustees

Inventors

• Leng Fenfei

Classifications

• C12Q1/6818 Primary

  involving interaction of two or more labels, e.g. resonant energy transfer · CPC title

• C07H21/00

  Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids · CPC title

• C12Q2521/519

  Topoisomerase · CPC title

• C12Q2565/133

  conformational analysis · CPC title

• C12Q2525/307

  Circular oligonucleotides · CPC title